50 Pharmaceutical Companies Raise Medicine Prices by Up to 2000 Percent

The Pakistan medicine price hike has become a major public concern after the federal health minister revealed that 50 pharmaceutical companies raised medicine prices by up to 2,000 percent. The disclosure, made on 31 October 2026, followed a third-party audit that exposed the scale of the increases. The government has now issued show-cause notices to all the companies involved.

For patients and families, the numbers are hard to ignore. A rise running into thousands of percent can force patients to skip doses, switch to weaker alternatives, or borrow money to stay on treatment.

The Pakistan medicine price hike also raises a wider question about how drug prices are set in the country. Companies argue they need room to cover costs and keep investing, while patients argue that medicines are not ordinary goods and excessive pricing puts lives at risk.

Pakistan medicine price hike: What the Minister Revealed

Federal Health Minister Mustafa Kamal revealed the figures while speaking about the audit findings. The third-party audit, he said, showed that 50 pharmaceutical companies increased prices by up to 2,000 percent, and the government issued show-cause notices to every company named.

A show-cause notice is not a final punishment. It gives a company a chance to explain its pricing before further action is taken. The final outcome for each company will depend on its response and on the review now under way.

The minister did not name the companies, and no list of individual medicines or their old and new prices was published with the announcement. Until the review is complete, it would be wrong to treat every product from these companies as equally affected.

Why Prices Were Allowed to Rise After 2022

The minister explained that companies were allowed to increase the prices of non-essential medicines after 2022. The policy was meant to give firms some flexibility on products not classed as essential, while keeping tighter control over medicines that patients cannot do without.

Not every price rise since 2022 was wrong, but some companies went far beyond what the policy intended, and the audit has now put a number on how far.

He also defended reasonable increases, arguing companies need reasonable returns to keep investing and ensure essential drugs remain available. Without that return, firms may stop making a medicine altogether.

To make the point, he cited a cancer medicine that disappeared from the market because its price was not increased enough to meet the company's requirements. The example was left unnamed, but the message was clear: a price kept too low can also drive a needed drug out of supply.

The Government Response and the Affordability Debate

A committee headed by the Finance Minister will review the Pakistan medicine price hike and decide on future increases, weighing the health impact alongside fiscal and industrial effects.

The minister has also said the pricing matter is under cabinet consideration. Major changes to the pricing framework will need approval at the highest level of government. Meanwhile, the show-cause process runs in parallel.

The minister acknowledged rising inflation affects almost everything, and the government must balance public affordability with industry investment. That balance is the heart of the Pakistan medicine price hike debate.

Patients need medicines they can afford every month, without fail, and a sudden increase can break a household budget. Manufacturers, meanwhile, face rising costs for raw materials, energy, and packaging, and warn that frozen prices can lead to shortages.

The minister has argued the government should withdraw from direct price regulation and let market forces decide, warning that unchanged prices could cause shortages forcing patients to buy at three times the price on the black market. Critics reply that market forces do not protect patients who have no choice about their medicine.

There is also a transparency angle. The minister has pointed to reforms at the Drug Regulatory Authority of Pakistan, which he says has been made transparent and digitalised. More than 86,000 medicines are registered under the Track and Trace System, which lets consumers scan a product to check its authenticity and price.

Registration is now completed within 21 days, and more than 5,000 cases were processed in the eight months since the shift to digital certification.

These steps do not by themselves end the Pakistan medicine price hike, but they give patients and regulators better information.

Frequently Asked Questions

What is the Pakistan medicine price hike about?

The Pakistan medicine price hike refers to the disclosure that 50 pharmaceutical companies raised medicine prices by up to 2,000 percent, as exposed by a third-party audit. The government has issued show-cause notices to all involved and formed a committee to review prices.

Which companies raised prices, and by how much?

The minister said 50 companies were involved, with increases of up to 2,000 percent. No company names or individual medicine prices were published with the announcement, so specific products should not be assumed to have risen by the maximum figure.

Why were companies allowed to raise prices after 2022?

Companies were allowed to increase prices of non-essential medicines after 2022. The minister said several firms took advantage of that policy and raised prices excessively, which is why the audit findings and show-cause notices have followed.

What will the review committee do?

The committee, headed by the Finance Minister, will review the Pakistan medicine price hike and decide on future increases. The pricing matter is also under cabinet consideration, so major changes to the framework would need approval at that level.

Will medicine prices come down for patients?

That is not yet known. The outcome will depend on the companies' responses to the show-cause notices and on the committee's decisions. Patients should watch for official announcements rather than assuming any particular price change in advance.